Clover Health Investments (CLOV) Posts Q4 2025 Earnings

​Clover Health Investments, Corp. (NASDAQ:CLOV) is one of the Best 52-Week Low Penny Stocks to Invest In. On February 26, Clover Health Investments, Corp. (NASDAQ:CLOV) released its fiscal Q4 2025 earnings. The company grew its revenue by 44.74% year-over-year to $487.7 million and topped expectations by $20.65 million. The EPS was negative $0.10 but remained in-line with the expectations.

​Clover Health reported 38% year-over-year growth in Medicare advantage membership, ending the year with 113,803 members. Moreover, the full-year revenue reached $1.9 billion, reflecting 40% increase from fiscal 2024. Management noted 2025 to be a year of execution driven by strong member growth.

​Looking ahead, the company expects 2026 to be the first profitable year on a GAAP net income basis, with net income ranging from breakeven to $20 million. Management expects to grow membership by 46% in 2026. Revenue for the year is projected between $2.81 billion and $2.92 billion, implying 49% year-over-year growth at the midpoint.

​Clover Health Investments, Corp. (NASDAQ:CLOV) is a healthcare technology company focused on improving medical outcomes for seniors through Medicare Advantage plans and its proprietary software platform, Clover Assistant. It operates as a next-generation insurer providing PPO and HMO plans to Medicare beneficiaries.

While we acknowledge the potential of CLOV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. Follow Insider Monkey on Google News.